Northern Trust Corp Orchard Therapeutics PLC Transaction History

Northern Trust Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.24 - $4.29 $58,349 - $111,750	-26,049 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$4.39 - $7.23 $79,393 - $130,754	-18,085 Reduced 40.98%	26,049 $114,000
Q1 2021 May 12, 2021	BUY	$4.39 - $9.08 $39,154 - $80,984	8,919 Added 25.33%	44,134 $320,000
Q4 2020 Feb 11, 2021	SELL	$3.86 - $5.07 $4,029 - $5,293	-1,044 Reduced 2.88%	35,215 $152,000
Q3 2020 Nov 16, 2020	BUY	$4.11 - $6.45 $213 - $335	52 Added 0.14%	36,259 $149,000
Q2 2020 Aug 14, 2020	SELL	$5.75 - $11.99 $8,711 - $18,164	-1,515 Reduced 4.02%	36,207 $217,000
Q1 2020 May 14, 2020	SELL	$5.65 - $15.71 $10,294 - $28,623	-1,822 Reduced 4.61%	37,722 $284,000
Q4 2019 Feb 14, 2020	SELL	$10.15 - $15.58 $2,283 - $3,505	-225 Reduced 0.57%	39,544 $544,000
Q3 2019 Nov 13, 2019	BUY	$11.88 - $16.72 $403 - $568	34 Added 0.09%	39,769 $472,000
Q2 2019 Aug 13, 2019	BUY	$13.2 - $20.63 $48,774 - $76,227	3,695 Added 10.25%	39,735 $556,000
Q1 2019 May 13, 2019	SELL	$12.01 - $19.49 $9,259 - $15,026	-771 Reduced 2.09%	36,040 $644,000
Q4 2018 Feb 12, 2019	BUY	$12.4 - $18.7 $456,456 - $688,365	36,811 New	36,811 $579,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.